Show simple item record

dc.contributor.authorSartor, O
dc.contributor.authorColeman, R
dc.contributor.authorNilsson, S
dc.contributor.authorHeinrich, D
dc.contributor.authorHelle, S
dc.contributor.authorO'Sullivan, J
dc.contributor.authorFosså, S
dc.contributor.authorChodacki, A
dc.contributor.authorWiechno, P
dc.contributor.authorLogue, John P
dc.contributor.authorWidmark, A
dc.contributor.authorJohannessen, D
dc.contributor.authorHoskin, P
dc.contributor.authorJames, N
dc.contributor.authorSolberg, A
dc.contributor.authorSyndikus, I
dc.contributor.authorVogelzang, N
dc.contributor.authorO'Bryan-Tear, C
dc.contributor.authorShan, M
dc.contributor.authorBruland, O
dc.contributor.authorParker, C
dc.date.accessioned2014-07-08T15:03:42Z
dc.date.available2014-07-08T15:03:42Z
dc.date.issued2014-06
dc.identifier.citationEffect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. 2014, 15 (7):738-46 Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid24836273
dc.identifier.doi10.1016/S1470-2045(14)70183-4
dc.identifier.urihttp://hdl.handle.net/10541/322637
dc.description.abstractBone metastases frequently cause skeletal events in patients with metastatic castration-resistant prostate cancer. Radium-223 dichloride (radium-223) selectively targets bone metastases with high-energy, short-range α-particles. We assessed the effect of radium-223 compared with placebo in patients with castration-resistant prostate cancer and bone metastases.
dc.language.isoenen
dc.rightsArchived with thanks to The lancet oncologyen
dc.titleEffect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.en
dc.typeArticleen
dc.contributor.departmentTulane Cancer Center, New Orleans, LA, USA.en
dc.identifier.journalThe Lancet Oncologyen
html.description.abstractBone metastases frequently cause skeletal events in patients with metastatic castration-resistant prostate cancer. Radium-223 dichloride (radium-223) selectively targets bone metastases with high-energy, short-range α-particles. We assessed the effect of radium-223 compared with placebo in patients with castration-resistant prostate cancer and bone metastases.


Files in this item

This item appears in the following Collection(s)

Show simple item record